cabotegravir
Selected indexed studies
- Cabotegravir. (, 2012) [PMID:37384749]
- Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women. (N Engl J Med, 2021) [PMID:34379922]
- Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial. (Lancet, 2022) [PMID:35378077]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial. (2023) pubmed
- Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women. (2021) pubmed
- Cabotegravir. (2012) pubmed
- Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial. (2022) pubmed
- Cabotegravir Plus Rilpivirine: First Approval. (2020) pubmed
- Cabotegravir/Rilpivirine: the last FDA-approved drug to treat HIV. (2022) pubmed
- Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection. (2020) pubmed
- Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression. (2020) pubmed
- Cabotegravir-Global Access to Long-Acting Pre-exposure Prophylaxis for HIV. (2023) pubmed
- Cabotegravir: The first long-acting injectable for HIV pre-exposure prophylaxis. (2022) pubmed